Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UGN-501 in Recurrent Non-muscle Invasive Bladder Cancer
NCT07725796Phase 1Recruiting
- Sponsor
- UroGen Pharma
- Start
- Sep 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ICVB-1042 in non-muscle-invasive bladder cancer (NMIBC), sponsored by UroGen Pharma. Primary endpoints: Incidence of dose-limiting toxicities and treatment-emergent adverse events at 15 months, Concentration of UGN-501 in blood and urine at 12 weeks and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
ICVB-1042
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07725796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07725796.